Evolent Health CEO Frank Williams Joins Syapse Board of Directors

Former CEO and chairman of The Advisory Board Company brings deep expertise helping health systems transform to value-based care


Williams Comp

San Francisco, Calif. (March 1, 2018) – Syapse, a leading precision medicine company, announced today that Frank Williams, the co-founder and CEO of Evolent Health, has joined the company’s board of directors.

Williams, a healthcare industry veteran and former executive chairman and CEO of The Advisory Board Company, brings deep expertise in helping health systems evolve to a value-based care model, focused on improving clinical outcomes and financial results. He started Evolent Health in 2011 to change the way healthcare is delivered in the U.S. by enabling health systems to gain the operational scale, financial partnerships, and clinical capabilities they need to deliver better patient outcomes at lower cost.

“To truly make precision medicine a reality for every patient, we must focus on giving oncologists the data they need to make targeted treatment decisions,” Williams said. “Syapse is on a mission to do just that, and I’m thrilled to bring my expertise working with large community health systems to the table to advance this effort. I look forward to working together to bring better cancer care to more patients.”

Williams will provide strategic advice to Syapse during a time of rapid growth for the company. Syapse raised $30 million in Series D financing in late 2017, expanded to Asia earlier this year, and recently announced new partnerships with Roche and Medidata to advance precision medicine for health systems.

“Frank’s experience helping health systems evolve to a new model of care and his philosophy of serving as a trusted partner to them is perfectly aligned with Syapse’s mission,” said Ken Tarkoff, CEO of Syapse. “I am honored to welcome Frank to the Syapse board, and I know his insights and expertise will be crucial as we expand our partnerships across the industry and advance precision medicine for health systems.”

About Syapse

Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our software platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income. Our customers—including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health—manage one million active cancer cases at nearly 300 hospitals in 25 states. Headquartered in San Francisco, Syapse is backed by investors including Social Capital, Safeguard Scientifics (NYSE: SFE), Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures.